Bruker Acquires Optical Cell Imaging Company Phasefocus
BILLERICA, Massachusetts ─ December 22, 2023 ─ Bruker today announced that it has signed a definitive agreement to acquire Phasefocus Holdings Limited, a privately held company that has leading expertise in imaging and image processing algorithms. Phasefocus has deployed their expertise to develop a novel optical microscope, called Livecyte, for label free imaging. Bruker’s global reach will help build on Phasefocus’ success to date. Financial details of the transaction were not disclosed.
Headquartered in Sheffield, UK, Phasefocus was founded in 2006 and have developed the Livecyte product based on strong algorithms and patented technology. Phasefocus’ microscopy capabilities will enhance Bruker’s existing portfolio, enabling new research advances in a range of cell imaging applications. This acquisition is another step forward in Bruker’s portfolio transformation.
“Phasefocus has extensive image processing and algorithm expertise that they have nicely deployed in their Livecyte product,” said Dr. Frank Burgaezy, President AXS division. “This is a good addition to our broad imaging portfolio and their technology will enable us to drive further product developments.”
“We are very pleased to join Bruker,” added Dr. Martin Humphry, CEO of Phasefocus. “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our products for investigation of dynamic single cell behavior.”
About Phasefocus
Based in Sheffield, UK, Phasefocus is a private company founded in 2006 from University of Sheffield research.
Phasefocus is changing what is possible in live cell assays, helping scientists uncover subtle differences in cell behaviour across whole cell populations.
Livecyte, Phasefocus's flagship product, delivers an unprecedented level of single cell data from live cells. High-contrast label-free imaging, correlative fluorescence and powerful automated image analysis algorithms result in high-content time-lapse outputs from standard 96-well plate assays.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
Media Contact:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com